212 related articles for article (PubMed ID: 1000510)
1. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
[TBL] [Abstract][Full Text] [Related]
3. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.
Sirotnak FM; Donsback RC
Cancer Res; 1975 Jul; 35(7):1737-44. PubMed ID: 1169115
[TBL] [Abstract][Full Text] [Related]
4. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.
Poser RG; Sirotnak FM; Chello PL
Cancer Res; 1981 Nov; 41(11 Pt 1):4441-6. PubMed ID: 6171339
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
[No Abstract] [Full Text] [Related]
6. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.
Whitehead VM
Cancer Res; 1977 Feb; 37(2):408-12. PubMed ID: 832265
[TBL] [Abstract][Full Text] [Related]
7. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
8. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
Sirotnak FM; Donsbach RC
Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse.
Sirotnak FM; Moccio DM
Cancer Res; 1980 Apr; 40(4):1230-4. PubMed ID: 7357552
[TBL] [Abstract][Full Text] [Related]
10. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo.
Priest DG; Bunni M; Sirotnak FM
Cancer Res; 1989 Aug; 49(15):4204-9. PubMed ID: 2743307
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
Chou TC; Hutchinson DJ; Schmid FA; Philips FS
Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
[TBL] [Abstract][Full Text] [Related]
12. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
[TBL] [Abstract][Full Text] [Related]
13. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
Sirotnak FM; Poser RE; Barrueco JR
Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
[TBL] [Abstract][Full Text] [Related]
15. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro.
Samuels LL; Moccio DM; Sirotnak FM
Cancer Res; 1985 Apr; 45(4):1488-95. PubMed ID: 3978616
[TBL] [Abstract][Full Text] [Related]
16. The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells.
Sirotnak FM; Donsbach RC
Cancer Res; 1974 Dec; 34(12):332-40. PubMed ID: 4429954
[No Abstract] [Full Text] [Related]
17. Hydrolytic cleavage of methotrexate gamma-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse.
Samuels LL; Goutas LJ; Priest DG; Piper JR; Sirotnak FM
Cancer Res; 1986 May; 46(5):2230-5. PubMed ID: 2421872
[TBL] [Abstract][Full Text] [Related]
18. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo.
Sirotnak FM; Moccio DM; Kelleher LE; Goutas LJ
Cancer Res; 1981 Nov; 41(11 Pt 1):4447-52. PubMed ID: 7306968
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
20. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
Chabner BA; Young RC
J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
